Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC

Key Points

• Exchange Traded Concepts LLC increased its Gilead Sciences stake by 427.7% in the second quarter, acquiring 216,275 additional shares for a total holding of 266,845 shares valued at approximately $33.7 million. Institutional investors collectively own 83.67% of Gilead’s stock.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above estimates, while earnings of $(6.75) per share exceeded expectations. Growth was driven by Biktarvy, HIV prevention products and contributions from Trodelvy and Livdelzi.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and a $158.04 average price target, although some firms recently lowered targets or ratings. Gilead also declared a quarterly dividend of $0.82 per share, representing a 2.4% yield.

Exchange Traded Concepts LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 427.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 266,845 shares of the biopharmaceutical company's stock after purchasing an additional 216,275 shares during the period. Exchange Traded Concepts LLC's holdings in Gilead Sciences were worth $33,713,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Aviva PLC boosted its stake in Gilead Sciences by 5.4% during the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company's stock valued at $141,978,000 after purchasing an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new stake in shares of Gilead Sciences in the 4th quarter worth $1,418,000. NBC Securities Inc. lifted its holdings in shares of Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company's stock valued at $2,105,000 after buying an additional 10,296 shares during the period. Flputnam Investment Management Co. lifted its holdings in shares of Gilead Sciences by 66.5% in the fourth quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company's stock valued at $12,978,000 after buying an additional 42,243 shares during the period. Finally, Farther Finance Advisors LLC boosted its stake in Gilead Sciences by 43.9% during the fourth quarter. Farther Finance Advisors LLC now owns 56,812 shares of the biopharmaceutical company's stock valued at $6,973,000 after buying an additional 17,325 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Wall Street Zen lowered Gilead Sciences from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Truist Financial lowered their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Needham & Company LLC reiterated a "buy" rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Daiwa Securities Group cut their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research note on Tuesday, May 19th. Finally, Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a report on Monday, July 27th. Twenty-four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $158.04.

Gilead Sciences Trading Up 1.7%

Shares of NASDAQ GILD opened at $138.14 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a market cap of $171.29 billion, a price-to-earnings ratio of -51.74 and a beta of 0.32. The business has a fifty day simple moving average of $129.93 and a 200-day simple moving average of $136.44.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the company earned $2.01 EPS. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $6,568,860 over the last 90 days. 0.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source